Ayala R et al. BMS-986158, a potent BET inhibitor, as monotherapy and in combination with ruxolitinib or fedratinib in intermediate- or high-risk myelofibrosis: First results from a phase 1/2 study. ASH 2022;Abstract 4346.

Gerds AT et al. Updated results from the momentum phase 3 study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. ASH 2022;Abstract 627.

Gill H et al. A phase 2 study of the LSD1 inhibitor bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET). ASH 2022;Abstract 740.

Guglielmelli P et al. JAK2V617F molecular response to ruxolitinib in patients with PV and ET Is associated with lower risk of progression to secondary myelofibrosis. ASH 2022;Abstract 741.

Guglielmelli P et al. Molecular characterization of response/loss-of-response to ruxolitinib in patients with myelofibrosis. ASH 2022;Abstract 342.

Gupta V et al. Safety and efficacy of fedratinib in patients with primary (P), post-polycythemia vera (post-PV), and post-essential thrombocythemia (post-ET) myelofibrosis (MF) previously treated with ruxolitinib: Primary analysis of the FREEDOM trial. ASH 2022;Abstract 1711.

Harrison CN et al. Ruxolitinib versus best available therapy for PV intolerant or resistant to hydroxycarbamide in a randomized trial. ASH 2022;Abstract 739.

Koschmieder S et al. Ruxolitinib versus best available therapy in patients with essential thrombocythemia: Pre-specified interim analysis of the randomized phase 2b ruxobeat clinical trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN). ASH 2022;Abstract 742.

Mascarenhas J et al. PACIFICA: A randomized, controlled phase 3 study of pacritinib versus physician’s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. ASH 2022;Abstract 4316.

Mascarenhas J et al. Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis: Durability of response and safety beyond week 24. ASH 2022;Abstract 238.

Mascarenhas J et al. The use of fedratinib for myelofibrosis as a potential bridge to hematopoietic stem cell transplantation after ruxolitinib failure: Real-world assessment of treatment characteristics and spleen, symptom, and hematologic response. ASH 2022;Abstract 2312.

Oh ST et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. ASH 2022;Abstract 628.

Passamonti F et al. The combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis mediates responses suggestive of disease modification. ASH 2022;Abstract 237.

Reis E et al. Discovery of INCA033989, a monoclonal antibody that selectively antagonizes mutant calreticulin oncogenic function in myeloproliferative neoplasms (MPNs). ASH 2022;Abstract 6.

Yacoub A et al. Efficacy and safety of add-on parsaclisib to ruxolitinib therapy in myelofibrosis patients with suboptimal response to ruxolitinib: Final results from a phase 2 study. ASH 2022;Abstract 236.